Quarterly report [Sections 13 or 15(d)]

Note 2 - Significant Accounting Policies (Details Textual)

v3.26.3
Note 2 - Significant Accounting Policies (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2025
Jan. 31, 2025
Oct. 23, 2024
Insurance Premiums Dues Subscription and Software Cost Paid In Advance $ 10,000   $ 10,000          
Cash, FDIC Insured Amount $ 250,000   $ 250,000          
Weighted Average Number of Shares Outstanding, Basic (in shares) [1] 8,561,371 7,123,849 8,546,516 7,036,937        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)     849,606 715,315        
Research and Development Expense $ 4,436,543 $ 2,589,749 $ 12,690,621 $ 5,963,124        
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense     0 $ 0        
License Agreement [Member]                
Initial Cash Payment for License Agreement         $ 1,000,000     $ 1,000,000
Additional Cash Payment for License Agreement             $ 3,000,000 $ 3,000,000
License Agreement, Upfront Payments [Member]                
Research and Development Expense         4,000,000      
License Agreement, Value of Common Stock [Member]                
Research and Development Expense         $ 4,600,000      
Fair Value, Recurring [Member]                
Liabilities, Fair Value Disclosure $ 0   $ 0     $ 0    
[1] Pre-funded warrants outstanding during the three and nine months ended September 30, 2026 and 2025, are exercisable at a nominal price and are considered, in substance, equivalent to outstanding common stock. Accordingly, such pre-funded warrants have been included in the calculation of weighted-average shares of common stock outstanding for purposes of basic and diluted net income (loss) per share.